<table id="_RefID0ESJAG" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6. Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Trials or Predicted Interactions [see Dosage and Administration (2)]</caption>
<col width="29%"></col>
<col width="20%"></col>
<col width="50%"></col>
<tbody>
<tr>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="bottom">
<paragraph>
<content stylecode="bold">Concomitant Drug Class:</content>
<br/>
<content stylecode="bold">Drug Name</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="bottom">
<paragraph>
<content stylecode="bold">Effect on Concentration of Dolutegravir and/or Concomitant Drug</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="bottom">
<paragraph>
<content stylecode="bold">Clinical Comment</content>
</paragraph>
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode="Rrule Lrule Botrule " valign="bottom">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">HIV-1 Antiviral Agents</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
</paragraph>
<paragraph>Etravirine
             
     
      <sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use of TIVICAY with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
</paragraph>
<paragraph>Efavirenz
             
     
      <sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Adjust dose of TIVICAY to 50 mg twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients.</paragraph>
<paragraph>In pediatric patients, increase the weight-based dose to twice daily (Table 2).</paragraph>
<paragraph>Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.
             
     
      <sup>b</sup>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
</paragraph>
<paragraph>Nevirapine</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Avoid coadministration with nevirapine because there are insufficient data to make dosing recommendations.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Protease inhibitor:</content>
</paragraph>
<paragraph>Fosamprenavir/ritonavir
             
     
      <sup>a</sup>
</paragraph>
<paragraph>Tipranavir/ritonavir
             
     
      <sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Adjust dose of TIVICAY to 50 mg twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. </paragraph>
<paragraph>In pediatric patients, increase the weight-based dose to twice daily (Table 2).</paragraph>
<paragraph>Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.
             
     
      <sup>b</sup>
</paragraph>
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode="Rrule Lrule Botrule " valign="bottom">
<paragraph>
<content stylecode="bold">
<content stylecode="italics">Other Agents</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Carbamazepine
             
     
      <sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Adjust dose of TIVICAY to 50 mg twice daily in treatment-naïve or treatment-experienced, INSTI-naïve adult patients. </paragraph>
<paragraph>In pediatric patients, increase the weight-based dose to twice daily (Table 2).</paragraph>
<paragraph>Use alternative treatment that does not include carbamazepine where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.
             
     
      <sup>b</sup>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Oxcarbazepine
             
     
      <br/>Phenytoin
             
     
      <br/>Phenobarbital
             
     
      <br/>St. John’s wort (
             
     
      <content stylecode="italics">Hypericum perforatum</content>)
            
    
     </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Avoid coadministration with TIVICAY because there are insufficient data to make dosing recommendations.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Medications containing polyvalent cations</content>
<br/>
<content stylecode="bold">(e.g., Mg or Al):</content>
</paragraph>
<paragraph>Cation-containing antacids
             
     
      <sup>a</sup> or laxatives
             
     
      <br/>Sucralfate
             
     
      <br/>Buffered medications
            
    
     </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Administer TIVICAY 2 hours before or 6 hours after taking medications containing polyvalent cations.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Oral calcium or iron supplements, including multivitamins containing calcium or iron</content>
<sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Administer TIVICAY 2 hours before or 6 hours after taking supplements containing calcium or iron. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Metformin</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↑Metformin</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>With concomitant use, limit the total daily dose of metformin to 1,000 mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment. Monitoring of blood glucose when initiating concomitant use and after withdrawal of TIVICAY is recommended.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Rifampin
             
     
      <sup>a</sup>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>↓Dolutegravir</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Adjust dose of TIVICAY to 50 mg twice daily for treatment-naïve and treatment-experienced, INSTI-naïve adult patients. </paragraph>
<paragraph>In pediatric patients, increase the weight-based dose to twice daily (Table 2).</paragraph>
<paragraph>Use alternatives to rifampin where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.
             
     
      <sup>b</sup>
</paragraph>
</td>
</tr>
</tbody>
</table>